Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

Table 2 Quality assessment results of economic evaluation reporting using the CHEERS checklist

Item (Item No)	Number of studies met the recommendations	Percentage (%)	%Agreement†
Target population and subgroups (4)	59/59	100	98
Study perspective (6)	50/59	85	81
Comparators (7)	58/59	98	98
Time horizon (8)	54/59	92	98
Discount rate for costs and outcomes (9) ^††	32/39	82	86
Measurement of effectiveness (Single study-based estimates) (11a)^#	50/50	100	95
Measurement of effectiveness (Synthesis-based estimates) (11b) ^##	9/9	100	95
Estimating resources and costs (Single study-based EE) (13a)*	9/9	100	95
Estimating resources and costs (Model-based EE) (13b)**	50/50	100	95
Study parameters (18)	50/59	85	84
Incremental costs and outcomes (19)	57/59	97	95
Characterizing uncertainty (Single study-based EE) (20a)*	2/9	22	98
Characterizing uncertainty (Model-based EE) (20b)**	50/50	100	100
Source of funding (23)	47/59	80	95
Conflicts of interest (24)	46/59	78	97

EE: Economic evaluation
† Percent agreement between two independent raters
†† The denominator for the calculations is the studies that reported the discount rate for costs and/or outcomes were from a study period longer than one year, including 39 studies
# The denominator for the calculations is a single study-based estimate of clinical effectiveness data, including 50 studies
## The denominator for the calculations is synthesis-based estimates of clinical effectiveness data, including 9 studies
* The denominator for the calculations is a single study-based economic evaluation, including 9 studies
** The denominator for the calculations is a single model-based economic evaluation, including 50 studies